TW201805007A - 依據ａｕｃ給與曲貝德生之方法 - Google Patents

依據ａｕｃ給與曲貝德生之方法 Download PDF

Info

Publication number: TW201805007A
Authority: TW; Taiwan
Prior art keywords: auc; days; trabexide; dose; hours
Prior art date: 2016-07-08

Application number

TW106123030A

Other languages

English (en)

Chinese (zh)

Inventor

旺趙

Original Assignee

奧圖泰利克有限責任公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-08

Filing date

2017-07-10

Publication date

2018-02-16

2017-07-10 Application filed by 奧圖泰利克有限責任公司 filed Critical 奧圖泰利克有限責任公司

2018-02-16 Publication of TW201805007A publication Critical patent/TW201805007A/zh

Links

238000000034 method Methods 0.000 title claims abstract description 49
FNCMIJWGZNHSBF-UHFFFAOYSA-N trabedersen Chemical compound CC1=CN(C2CC(O)C(COP(=O)(S)OC3CC(OC3COP(=O)(S)OC4CC(OC4COP(=O)(S)OC5CC(OC5COP(=O)(S)OC6CC(OC6COP(=O)(S)OC7CC(OC7COP(=O)(S)OC8CC(OC8COP(=O)(S)OC9CC(OC9COP(=O)(S)OC%10CC(OC%10COP(=O)(S)OC%11CC(OC%11COP(=O)(S)OC%12CC(OC%12COP(=O)(S)OC%13CC(OC%13COP(=O)(S)OC%14CC(OC%14COP(=O)(S)OC%15CC(OC%15CO)N%16C=CC(=NC%16=O)N)n%17cnc%18C(=O)NC(=Nc%17%18)N)n%19cnc%20C(=O)NC(=Nc%19%20)N)N%21C=CC(=NC%21=O)N)n%22cnc%23c(N)ncnc%22%23)N%24C=C(C)C(=O)NC%24=O)n%25cnc%26C(=O)NC(=Nc%25%26)N)N%27C=C(C)C(=O)NC%27=O)N%28C=CC(=NC%28=O)N)N%29C=C(C)C(=O)NC%29=O)n%30cnc%31c(N)ncnc%30%31)N%32C=C(C)C(=O)NC%32=O)N%33C=C(C)C(=O)NC%33=O)O2)C(=O)NC1=O.CC%34=CN(C%35CC(OP(=O)(S)OCC%36OC(CC%36OP(=O)(S)OCC%37OC(CC%37OP(=O)(S)OCC%38OC(CC%38O)n%39cnc%40c(N)ncnc%39%40)N%41C=C(C)C(=O)NC%41=O)n%42cnc%43C(=O)NC(=Nc%42%43)N)C(COP(=O)S)O%35)C(=O)NC%34=O FNCMIJWGZNHSBF-UHFFFAOYSA-N 0.000 title abstract description 3
229950002824 trabedersen Drugs 0.000 title abstract description 3
239000003814 drug Substances 0.000 claims abstract description 68
229940079593 drug Drugs 0.000 claims abstract description 67
206010028980 Neoplasm Diseases 0.000 claims abstract description 50
201000011510 cancer Diseases 0.000 claims abstract description 25
239000002246 antineoplastic agent Substances 0.000 claims abstract description 13
229940127089 cytotoxic agent Drugs 0.000 claims abstract description 13
239000008280 blood Substances 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 8
201000001441 melanoma Diseases 0.000 claims description 6
230000001131 transforming effect Effects 0.000 claims description 5
206010060862 Prostate cancer Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
238000010521 absorption reaction Methods 0.000 claims description 4
230000036983 biotransformation Effects 0.000 claims description 3
230000029142 excretion Effects 0.000 claims description 3
230000004060 metabolic process Effects 0.000 claims description 3
230000001235 sensitizing effect Effects 0.000 abstract description 4
238000011282 treatment Methods 0.000 description 30
241001465754 Metazoa Species 0.000 description 9
231100000682 maximum tolerated dose Toxicity 0.000 description 9
238000012986 modification Methods 0.000 description 9
230000004048 modification Effects 0.000 description 9
208000003174 Brain Neoplasms Diseases 0.000 description 8
230000007160 gastrointestinal dysfunction Effects 0.000 description 8
206010061902 Pancreatic neoplasm Diseases 0.000 description 7
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
239000000203 mixture Substances 0.000 description 7
201000002528 pancreatic cancer Diseases 0.000 description 7
208000008443 pancreatic carcinoma Diseases 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
206010009944 Colon cancer Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
206010018338 Glioma Diseases 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
201000010099 disease Diseases 0.000 description 5
206010061311 nervous system neoplasm Diseases 0.000 description 5
208000032612 Glial tumor Diseases 0.000 description 4
230000002411 adverse Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
208000001333 Colorectal Neoplasms Diseases 0.000 description 3
241000283086 Equidae Species 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
231100000171 higher toxicity Toxicity 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
206010003571 Astrocytoma Diseases 0.000 description 2
241000282421 Canidae Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
241000282579 Pan Species 0.000 description 2
241000288906 Primates Species 0.000 description 2
241000282887 Suidae Species 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000003098 androgen Substances 0.000 description 2
208000024055 brain glioblastoma Diseases 0.000 description 2
201000011609 brain glioblastoma multiforme Diseases 0.000 description 2
239000012830 cancer therapeutic Substances 0.000 description 2
238000001818 capillary gel electrophoresis Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
231100000086 high toxicity Toxicity 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
208000023833 nerve sheath neoplasm Diseases 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
208000008511 optic nerve glioma Diseases 0.000 description 2
201000005528 peripheral nervous system neoplasm Diseases 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
238000000825 ultraviolet detection Methods 0.000 description 2
241000282672 Ateles sp. Species 0.000 description 1
241000157302 Bison bison athabascae Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000282324 Felis Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000221931 Hypomyces rosellus Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241000282339 Mustela Species 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010073338 Optic glioma Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006593 Urologic Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000013355 benign neoplasm of brain Diseases 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
201000007983 brain glioma Diseases 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
208000023437 ependymal tumor Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
208000029824 high grade glioma Diseases 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
208000030173 low grade glioma Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000011614 malignant glioma Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
201000004058 mixed glioma Diseases 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
201000011682 nervous system cancer Diseases 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
206010073131 oligoastrocytoma Diseases 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW106123030A 2016-07-08 2017-07-10 依據ａｕｃ給與曲貝德生之方法 TW201805007A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662360101P	2016-07-08	2016-07-08
US62/360,101		2016-07-08

Publications (1)

Publication Number	Publication Date
TW201805007A true TW201805007A (zh)	2018-02-16

Family

ID=60911990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW106123030A TW201805007A (zh)	2016-07-08	2017-07-10	依據ａｕｃ給與曲貝德生之方法

Country Status (2)

Country	Link
TW (1)	TW201805007A (fr)
WO (1)	WO2018009895A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2356234B1 (fr) *	2008-11-14	2017-08-16	Autotelic LLC	Dosage d'oligonucléotides adaptés pour le traitement de tumeurs
US20120114640A1 (en) *	2009-05-08	2012-05-10	Kulkarni Ashok B	MODULATION OF THE TGF- ß AND PI3K/AKT PATHWAYS IN THE DIAGNOSIS AND TREATMENT OF SQUAMOUS CELL CARCINOMA
WO2013173283A1 (fr) *	2012-05-16	2013-11-21	Novartis Ag	Régime posologique pour un inhibiteur de pi-3 kinase
PL2978846T3 (pl) *	2013-03-27	2020-09-21	Isarna Therapeutics Gmbh	Zmodyfikowany oligonukleotyd tgf-beta do zastosowania w sposobie zapobiegania i/lub leczenia choroby oftalmicznej

2017
- 2017-07-07 WO PCT/US2017/041242 patent/WO2018009895A1/fr not_active Ceased
- 2017-07-10 TW TW106123030A patent/TW201805007A/zh unknown

Also Published As

Publication number	Publication date
WO2018009895A1 (fr)	2018-01-11

Publication	Publication Date	Title
Lun et al.	2016	Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma
US20250228861A1 (en)	2025-07-17	Cancer Treatments Using MTA-Cooperative PRMT5 Inhibitors
KR102462177B1 (ko)	2022-11-04	Ｍｄｍ２ 억제제의 간헐적 투여
Gunda et al.	2014	Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways
Chan et al.	2013	RETRACTED ARTICLE: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
Sharma et al.	2014	Role of adenosine and the orexinergic perifornical hypothalamus in sleep-promoting effects of ethanol
Fischer et al.	2021	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases
Berlin et al.	2018	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
US10583111B2 (en)	2020-03-10	Method for preventing or treating diseases associated with the inhibition of EGFR
JP2018016659A (ja)	2018-02-01	神経障害性疼痛の治療用薬剤
Liang et al.	2019	MiR-34a affects dexmedetomidine-inhibited chronic inflammatory visceral pain by targeting to HDAC2
KR20170104114A (ko)	2017-09-14	암을 치료하기 위한 조성물과 방법
US20170226518A1 (en)	2017-08-10	Compositions and methods for treating cancer
US9963703B2 (en)	2018-05-08	Compositions and methods for treating pancreatic cancer
US20250387643A1 (en)	2025-12-25	Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy
US20200031920A1 (en)	2020-01-30	Combination Therapy for Treating Cancer
TW201805007A (zh)	2018-02-16	依據ａｕｃ給與曲貝德生之方法
Ningaraj et al.	2009	Activation of KATP channels increases anticancer drug delivery to brain tumors and survival
Ethemoglu et al.	2019	Effects of agomelatine on electrocorticogram activity on penicillin-induced seizure model of rats
KR20170104113A (ko)	2017-09-14	췌장암을 치료하기 위한 조성물과 방법
Li et al.	2024	Glioma induces atypical depression-like behaviors in mice through the 5-HT and glutamatergic synapse pathways
EP4353236A1 (fr)	2024-04-17	Composé et méthode de traitement d'effets secondaires gastro-intestinaux liés à la chimiothérapie
Chahardehi et al.	2026	Sonic Hedgehog Pathway Modulation in Medulloblastoma: Focus on Vismodegib (GDC‐0449)
WO2015153866A1 (fr)	2015-10-08	Thérapie anticancéreuse basée sur le ganetespib et un inhibiteur de l'egfr
HK40111076A (zh)	2024-12-27	Wee1抑制剂和用於治疗癌症的方法